Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00096200
Status:
COMPLETED
Last Update Posted:
2022-02-08
First Post:
2004-11-09
Brief Title:
Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer Primary Peritoneal Cancer or Fallopian Tube Cancer
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
A Phase II Trial Of BAY 43-9006 A Novel Raf Kinase Inhibitor Plus PaclitaxelCarboplatin In Women With Recurrent Platinum Sensitive Epithelial Ovarian Peritoneal Or Fallopian Tube Cancer
Status:
COMPLETED
Status Verified Date:
2022-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor Drugs used in chemotherapy such as paclitaxel and carboplatin work in different ways to stop tumor cells from dividing so they stop growing or die Giving sorafenib together with chemotherapy may kill more tumor cells This randomized phase II trial is studying how well giving sorafenib together with paclitaxel and carboplatin works in treating patients with recurrent ovarian cancer primary peritoneal cancer or fallopian tube cancer Sorafenib only group closed as of 10102008
Detailed Description:
PRIMARY OBJECTIVES
I Compare the progression-free and overall survival rate of patients with recurrent platinum-sensitive ovarian epithelial primary peritoneal or fallopian tube cancer treated with sorafenib with or without carboplatin and paclitaxel Arm I sorafenib only closed to accrual 10012008 II Evaluate the response rate and time to disease progression in patients treated with these regimens
OUTLINE This is a multicenter study Patients are stratified according to performance status and participating center
ARM I closed to accrual 10012008 Patients receive oral sorafenib twice daily on days 1-28Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity Patients with disease progression crossover to arm II
ARM II Patients receive oral sorafenib twice daily on days 2-19 Patients also receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1 Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity
I Compare the progression-free and overall survival rate of patients with recurrent platinum-sensitive ovarian epithelial primary peritoneal or fallopian tube cancer treated with sorafenib with or without carboplatin and paclitaxel Arm I sorafenib only closed to accrual 10012008 II Evaluate the response rate and time to disease progression in patients treated with these regimens
OUTLINE This is a multicenter study Patients are stratified according to performance status and participating center
ARM I closed to accrual 10012008 Patients receive oral sorafenib twice daily on days 1-28Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity Patients with disease progression crossover to arm II
ARM II Patients receive oral sorafenib twice daily on days 2-19 Patients also receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1 Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| U01CA062502 | NIH | CTEP | httpsreporternihgovquickSearchU01CA062502 |
| CASE 2804 | None | None | None |
| NCI-2009-00067 | REGISTRY | None | None |
| CDR0000390331 | None | None | None |
| 6557 | OTHER | None | None |
| N01CM62208 | NIH | None | None |
| CASE 2804 | OTHER | None | None |
| P30CA043703 | NIH | None | None |